BACKGROUND: Obesity is associated with poorer breast cancer-specific survival. The purpose of this study was to investigate the relationships between obesity and the presence of angiolymphatic invasion as well as other features of invasive breast cancer, including stage at presentation, estrogen receptor (ER) status, triple-negative phenotype, and tumor grade. METHODS: Detailed clinical and pathologic data were abstracted from the medical records of all 1,312 patients with stage I-III primary breast cancer who had breast surgery at the University of Michigan Comprehensive Cancer Center between January 1, 2000 and December 31, 2006. Bivariate and multivariate analyses were conducted to investigate the relationships between body mass index and tumor biologic features, controlling for menopausal status, diabetes and hypertension, hormone replacement therapy before diagnosis, race, and ethnicity. RESULTS: In multivariate analyses, severe obesity was independently associated with the presence of angiolymphatic invasion [odds ratio (OR) 1.80, 95% confidence interval (CI) 1.08-2.99, joint test of significance, P = 0.03]. Severe obesity was associated with lower likelihood of triple-negative breast cancer (OR 0.39, 95% CI 0.16-0.96). Among premenopausal women with diabetes, ER-negative (OR 5.22, 95% CI 1.12-24.29) and triple-negative (OR 14.8, 95% CI 1.92-113.91) disease was significantly more common. DISCUSSION: In this large sample of invasive breast cancers, obesity was independently associated with the presence of angiolymphatic invasion. Higher rates of angiolymphatic invasion among obese women may account in part for poorer outcomes among obese women with breast cancer.
BACKGROUND:Obesity is associated with poorer breast cancer-specific survival. The purpose of this study was to investigate the relationships between obesity and the presence of angiolymphatic invasion as well as other features of invasive breast cancer, including stage at presentation, estrogen receptor (ER) status, triple-negative phenotype, and tumor grade. METHODS: Detailed clinical and pathologic data were abstracted from the medical records of all 1,312 patients with stage I-III primary breast cancer who had breast surgery at the University of Michigan Comprehensive Cancer Center between January 1, 2000 and December 31, 2006. Bivariate and multivariate analyses were conducted to investigate the relationships between body mass index and tumor biologic features, controlling for menopausal status, diabetes and hypertension, hormone replacement therapy before diagnosis, race, and ethnicity. RESULTS: In multivariate analyses, severe obesity was independently associated with the presence of angiolymphatic invasion [odds ratio (OR) 1.80, 95% confidence interval (CI) 1.08-2.99, joint test of significance, P = 0.03]. Severe obesity was associated with lower likelihood of triple-negative breast cancer (OR 0.39, 95% CI 0.16-0.96). Among premenopausal women with diabetes, ER-negative (OR 5.22, 95% CI 1.12-24.29) and triple-negative (OR 14.8, 95% CI 1.92-113.91) disease was significantly more common. DISCUSSION: In this large sample of invasive breast cancers, obesity was independently associated with the presence of angiolymphatic invasion. Higher rates of angiolymphatic invasion among obesewomen may account in part for poorer outcomes among obesewomen with breast cancer.
Authors: Efstathios V Kotidis; George G Koliakos; Vasilios G Baltzopoulos; Konstantinos N Ioannidis; John G Yovos; Spiros T Papavramidis Journal: Obes Surg Date: 2006-11 Impact factor: 4.129
Authors: Sherene Loi; Roger L Milne; Michael L Friedlander; Margaret R E McCredie; Graham G Giles; John L Hopper; Kelly-Anne Phillips Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-07 Impact factor: 4.254
Authors: Maura K Whiteman; Susan D Hillis; Kathryn M Curtis; Jill A McDonald; Phyllis A Wingo; Polly A Marchbanks Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-08 Impact factor: 4.254
Authors: Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07-29 Impact factor: 4.254
Authors: Luigino Dal Maso; Antonella Zucchetto; Renato Talamini; Diego Serraino; Carmen F Stocco; Marina Vercelli; Fabio Falcini; Silvia Franceschi Journal: Int J Cancer Date: 2008-11-01 Impact factor: 7.396
Authors: Julie R Palmer; Nelsy Castro-Webb; Kimberly Bertrand; Traci N Bethea; Gerald V Denis Journal: Cancer Res Date: 2017-11-15 Impact factor: 12.701
Authors: Yoseph W Dance; Tova Meshulam; Alex J Seibel; Mackenzie C Obenreder; Matthew D Layne; Celeste M Nelson; Joe Tien Journal: Cell Mol Bioeng Date: 2021-08-24 Impact factor: 3.337
Authors: Gregory C Connolly; Saman Safadjou; Randeep Kashyap; Rui Chen; Mark S Orloff; Aram F Hezel Journal: BMC Gastroenterol Date: 2013-01-14 Impact factor: 3.067
Authors: Bella Pajares; Marina Pollán; Miguel Martín; John R Mackey; Ana Lluch; Joaquín Gavila; Charles Vogel; Manuel Ruiz-Borrego; Lourdes Calvo; Tadeusz Pienkowski; Álvaro Rodríguez-Lescure; Miguel Angel Seguí; Olivier Tredan; Antonio Antón; Manuel Ramos; María del Carmen Cámara; César Rodríguez-Martín; Eva Carrasco; Emilio Alba Journal: Breast Cancer Res Date: 2013-11-06 Impact factor: 6.466